

ComboMATCH/EAY191 Flowchart


Molecular Analysis for Combination Therapy Choice

ComboMATCH is a large precision medicine initiative that is evaluating new combinations of anti-cancer drugs in selected groups of adults and children with cancer. The drug combinations are based on strong early evidence that they may be more effective than single therapy in treating some cancers. ComboMATCH consists of multiple treatment trials; participants will be assigned to treatment based on laboratory tests that look at the genes of their tumor cells. The drug combinations are either two targeted therapies together, or a targeted drug with chemotherapy. Each treatment trial has its own research goals, patient eligibility criteria, and enrollment timeline.

ComboMATCH/EAY191 Eligibility Criteria*

- Locally advanced or metastatic solid tumors with measurable disease
- Must have progressed on at least one line of standard systemic therapy, OR have disease for which no standard treatment to prolong overall survival exists
- ECOG PS 0–2 OR Lansky/Karnofsky $\geq 50\%$
- ≥ 18 years old: tumor amenable to minimal risk biopsy and undergo a tumor biopsy to obtain samples for research, OR confirm availability of an archival FFPE tumor tissue specimen collected within 12 months prior to registration, without a complete/partial response to any intervening therapy
- < 18 years old: confirm willingness to submit of an archival FFPE tumor tissue specimen, if available, for research

*Refer to the protocol for complete eligibility details.



ComboMATCH is led by the ECOG-ACRIN Cancer Research Group and National Cancer Institute, with treatment trials by the Alliance for Clinical Trials in Oncology, Children's Oncology Group, NRG Oncology, and SWOG Cancer Research Network

